Search

Illumina Inc

Slēgts

SektorsVeselības aprūpe

190.2 -1.76

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

189.76

Max

191.09

Galvenie mērījumi

By Trading Economics

Ienākumi

-200M

134M

Pārdošana

-68M

1.1B

P/E

Sektora vidējais

35.397

60.549

EPS

1.15

Peļņas marža

12.282

Darbinieki

8,600

EBITDA

-219M

226M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

-16.63% downside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 30. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

9.9B

29B

Iepriekšējā atvēršanas cena

191.96

Iepriekšējā slēgšanas cena

190.2

Ziņu noskaņojums

By Acuity

5%

95%

2 / 342 Rangs Healthcare

Illumina Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. jūl. 20:06 UTC

Correlated Moves

Illumina Inc shares are lower amid a broader decline in the biotechnology sector. Market volatility is heightened due to geopolitical tensions involving the U.S. and Iran.

2026. g. 9. jūl. 19:11 UTC

News
Correlated Moves

Illumina Inc. appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, contributing to a rise in shares amid sector gains.

2026. g. 8. jūl. 20:04 UTC

Correlated Moves

Illumina Inc shares are lower today, influenced by declines in the Life Sciences Tools & Services sector and a drop in the Russell 2000 Index.

2026. g. 7. jūl. 21:41 UTC

Illumina Inc. shares are higher in after-market trading, reflecting ongoing strength despite earlier session pullbacks and broader caution in the technology sector.

2026. g. 6. jūl. 19:52 UTC

Social Media
News

Evercore ISI raised its price target on Illumina to $200, maintaining an Outperform rating. Shares are trading higher amid positive sentiment and social media discussions.

2026. g. 2. jūl. 23:06 UTC

Correlated Moves

Illumina Inc shares declined in after-market trading, reflecting broader trends despite positive movements in European equity indices, including a rise in the DAX.

2026. g. 1. jūl. 20:03 UTC

News

Piper Sandler raised Illumina's price target to $200, contributing to shares trading higher today. The company also expanded its board with a new appointment.

2026. g. 30. jūn. 20:01 UTC

News
Social Media

Illumina Inc shares are lower as Roche launches a competing gene sequencer at a lower price, challenging Illumina's market share in genetic testing technology.

2026. g. 29. jūn. 23:16 UTC

Illumina Inc shares are lower in after-market trading, with no specific news identified to explain the movement. Broader U.S. equities show mixed performance.

2026. g. 26. jūn. 23:16 UTC

Illumina Inc shares are trading lower in after-market hours. Broader market concerns over rising interest rates and inflation may be influencing investor behavior.

2026. g. 25. jūn. 23:26 UTC

Illumina Inc shares are higher in after-market trading, reflecting strong performance above their 20-day moving average despite no specific news driving the move.

2026. g. 24. jūn. 20:02 UTC

News
Social Media

Illumina Inc. shares are higher amid gains in the Life Sciences Tools & Services sector. Barclays raised its price target to $145 from $122.

2026. g. 23. jūn. 22:46 UTC

Illumina Inc shares are higher in after-market trading, reflecting a notable advance since Tuesday's close and strong performance near the upper end of its one-month range.

2026. g. 22. jūn. 19:32 UTC

Illumina Inc's shares are higher today, despite declines in the Nasdaq. The stock remains flat since Thursday, with no specific news driving the movement.

2026. g. 19. jūn. 00:02 UTC

Correlated Moves

Illumina Inc shares are lower in after-market hours, reflecting broader market sentiment as the Russell 2000 Index also declined slightly.

2026. g. 18. jūn. 23:01 UTC

Illumina Inc shares are lower in after-market hours following earlier gains. The stock showed unusual volatility during this session without identifiable news.

2026. g. 17. jūn. 20:03 UTC

Correlated Moves
Macro Event

Illumina Inc shares are lower today, driven by broader market declines and macroeconomic concerns related to the Federal Reserve's monetary policy decisions.

2026. g. 16. jūn. 19:56 UTC

Correlated Moves

Illumina Inc. shares are lower today, following a broader market decline. The stock remains above its 20-day moving average despite recent fluctuations.

2026. g. 15. jūn. 13:02 UTC

Correlated Moves

Illumina Inc shares are higher in pre-market trading, reflecting strong momentum since Friday's close and aligning with the broader Russell 2000 Index trend.

2026. g. 12. jūn. 19:56 UTC

Illumina Inc's shares are lower today, continuing a downward trend since Thursday. The stock remains above its 20-day moving average despite the decline.

2026. g. 11. jūn. 20:03 UTC

Correlated Moves
News

Illumina Inc launched its StrataMap Spatial Solution, enhancing gene detection capabilities. Shares are advancing in Thursday's session, recovering from earlier lows.

2026. g. 10. jūn. 23:11 UTC

Illumina Inc shares are higher in after-market trading, supported by a notable upward trend in the Life Sciences Tools & Services sub-sector.

2026. g. 9. jūn. 19:26 UTC

News

Illumina shares are advancing, supported by a consensus "Hold" rating from analysts and an average price target of $138.38.

2026. g. 8. jūn. 20:06 UTC

News

Illumina Inc launched the StrataMap Spatial Solution, yet shares are declining amid broader market sentiment and sector challenges.

2026. g. 5. jūn. 23:16 UTC

Correlated Moves

Illumina Inc shares are roughly flat in after-market trading, reflecting broader market dynamics amid a slight decline in the Russell 2000 Index.

2026. g. 4. jūn. 19:51 UTC

Illumina Inc shares are lower today, breaking a trend of higher closes since Wednesday. No specific news was identified to explain this decline.

2026. g. 3. jūn. 23:03 UTC

Illumina Inc shares are higher in after-market trading, maintaining levels above its 20-day moving average amid broader market concerns about inflation and geopolitical tensions.

2026. g. 2. jūn. 23:21 UTC

Correlated Moves

Illumina Inc shares declined in after-market trading, reflecting broader market trends amid mixed economic signals and a stronger-than-expected JOLTS job openings report.

2026. g. 1. jūn. 23:46 UTC

Illumina Inc shares are higher in after-market trading following a report showing U.S. manufacturing activity expanded for the fifth consecutive month.

2026. g. 29. maijs 20:03 UTC

Illumina Inc is higher in Friday's session, maintaining gains since Thursday's close. No specific news was identified to explain the price action.

Salīdzinājums

Cenas izmaiņa

Illumina Inc Prognoze

Cenas mērķis

By TipRanks

-16.63% uz leju

Prognoze 12 mēnešiem

Vidējais 158.57 USD  -16.63%

Augstākais 200 USD

Zemākais 95 USD

Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Illumina Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

14 ratings

7

Pirkt

4

Turēt

3

Pārdot

Noskaņojums

By Acuity

2 / 342 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Illumina Inc

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
help-icon Live chat